NCT02550327View on ClinicalTrials.gov

Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

June 14, 2021

Study Completion Date

June 14, 2021

Conditions
Pancreatic Adenocarcinoma
Interventions
DRUG

Nab-paclitaxel

125 mg/m2

DRUG

Gemcitabine

1000 mg/m2

DRUG

Cisplatin

25 mg/m2

DRUG

Anakinra

100 mg

Trial Locations (1)

75246

Baylor Charles A. Sammons Cancer Center, Dallas

Sponsors
All Listed Sponsors
lead

Baylor Research Institute

OTHER